Join our daily newsletter At The Bell to receive exclusive market insights
- NeuroScientific Biopharmaceuticals (NSB) says new biomarker data highlights the potential for its drug to be an effective treatment for multiple sclerosis (MS)
- Results from a preclinical study in vitro in human primary cell-based systems saw significantly reduced biomarkers for key drivers of immune responses in multiple sclerosis when using EmtinB
- The company says this indicates the strong therapeutic potential of the drug as a treatment for MS and intends to undertake further assessments through phase two studies
- NeuroScientific Biopharmaceuticals last traded at 33 cents on August 30
NeuroScientific Biopharmaceuticals (NSB) says new biomarker data has highlighted the potential for its drug to be an effective treatment for multiple sclerosis (MS).
MS is a progressive neurodegenerative disease in which the immune system eats away at the protective covering of nerves, disrupting communication between the brain and body.
A preclinical study was conducted by an independent contract research organisation in vitro in human primary cell-based systems. NeuroScientific says the trial results saw significantly reduced biomarkers for key drivers of immune responses in multiple sclerosis when using EmtinB.
EmtinB is a compound that binds to surface-based cell receptors which can stimulate neuroprotection and regeneration. Preclinical research has demonstrated the drug is safe and well tolerated at high concentrations and is able to penetrate the blood brain barrier.
EmtinB was shown to significantly reduce biomarkers and not cause any toxicity. The company said this indicates the strong therapeutic potential of EmtinB as a treatment for MS.
NeuroScientific’s Managing Director, Matt Liddelow, says it’s exciting to explore the potential therapeutic benefits of EmtinB, especially following the current studies that validate the drug’s potential to treat MS.
“Unlike currently available drugs for MS, EmtinB has the potential to regulate immune processes, protect and regenerate nerve cells, and upregulate myelination,” said Matt Liddelow.
Neuroscientific says it intends to further assess EmtinB for treating MS through phase two studies.
NeuroScientific Biopharmaceuticals last traded at 33 cents on August 30.
